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Aim: Quantitative and kinetic insights into the drug exposure-disease response rela-
tionship might enhance our knowledge on loss of response and support more effec-
tive monitoring of inflammatory activity by biomarkers in patients with inflammatory
bowel disease (IBD) treated with infliximab (IFX). This study aimed to derive recom-
mendations for dose adjustment and treatment optimisation based on mechanistic
characterisation of the relationship between IFX serum concentration and C-reactive
protein (CRP) concentration.
Methods: Data from an investigator-initiated trial included 121 patients with IBD
during IFX maintenance treatment. Serum concentrations of IFX, antidrug antibodies
(ADA), CRP, and disease-related covariates were determined at the mid-term and
end of a dosing interval. Data were analysed using a pharmacometric nonlinear
mixed-effects modelling approach. An IFX exposure-CRP model was generated and
applied to evaluate dosing regimens to achieve CRP remission.
Results: The generated quantitative model showed that IFX has the potential to
inhibit up to 72% (9% relative standard error [RSE]) of CRP synthesis in a patient. IFX
concentration leading to 90% of the maximum CRP synthesis inhibition was 18.4 μg/
mL (43% RSE). Presence of ADA was the most influential factor on IFX exposure.
With standard dosing strategy, ≥55% of ADA+ patients experienced CRP non-
remission. Shortening the dosing interval and co-therapy with immunomodulators
were found to be the most beneficial strategies to maintain CRP remission.
Conclusions: With the generated model we could for the first time establish a robust
relationship between IFX exposure and CRP synthesis inhibition, which could be
utilised for treatment optimisation in IBD patients.
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1 | INTRODUCTION
The inflammatory bowel diseases (IBDs), Crohn's disease and ulcera-
tive colitis, comprise a complex variety of diseases characterised by
chronic intestinal inflammation that may lead to irreversible damage
and are associated with poor quality of life. While the control of IBDs
has previously been of limited success, introduction of antitumour
necrosis factor α (TNFα) monoclonal antibodies, such as infliximab
(IFX), adalimumab and golimumab, brought about a notable advance-
ment.1 However, loss of response to the approved dosing regimen
posits major challenges and introduced the need for Therapeutic Drug
Monitoring (TDM), which finds clinical translations mostly with IFX.1
Furthermore, the choice of the most appropriate treatment target
to be tackled and effective monitoring biomarkers in IBD is itself a
complex task. Measures of clinical remission2 are subjective and thus
not appropriate for exploring exposure-response relationships of
drugs, whereas the more objective assessment of endoscopic disease
activity is less apt for long-term disease monitoring due to invasive-
ness. C-reactive protein (CRP) concentration has been found to be a
suitable surrogate marker due to its correlation with endoscopy3 and
favourable kinetic behaviour.4
The relationship between serum concentrations of IFX and vari-
ous disease outcomes has previously been investigated.5–10 However,
there is a lack of quantitative and kinetic knowledge of those relation-
ships. A pharmacometric framework, using the quantitative pharmaco-
kinetic/pharmacodynamics (PK/PD) population approach,11 in
comparison with a static relationship relating exposure and response
only at fixed time points, describes the time course of both drug expo-
sure and IBD activity, and additionally enables quantifying the variabil-
ity between patients in the investigated population, and identifying
and quantifying factors that impact drug exposure or disease activity.
The aim of this study was to derive recommendations for dose
adjustment and treatment optimisation based on mechanistic and
kinetic characterisation of the relationship between IFX dosing, IFX
serum concentration and CRP concentration.
2 | METHODS
2.1 | Study design
The data analysed in this study originated from an investigator-
initiated trial performed at the University Hospital of the Medical
University of Vienna. The study was conducted in accordance with
ethical standards and was approved the institutional review board of
the Medical University of Vienna. Written informed consent prior to
inclusion was obtained from all patients.
Adult patients (n = 121) diagnosed with IBD (89 with Crohn's
disease, 31 with ulcerative colitis (UC) and one patient with
undetermined IBD type) in maintenance IFX treatment were included
in the study, regardless of CRP concentration; patients with obvious
conditions associated with increased CRP concentration (particularly
infectious conditions) were excluded. The patients received IFX at
absolute doses ranging from 100 to 1300 mg (median 400 mg;
1-11 mg/kg, median 5.6 mg/kg) at dosing intervals ranging from 3 to
12 weeks (median 8 weeks). Blood samples (n = 388) were taken at
Cmin (minimum or trough concentration) and at the middle of the dos-
ing interval as part of Therapeutic Drug Monitoring in the period
2010-2012. Serum concentrations of IFX, antidrug antibodies (ADA),
CRP, albumin and other relevant laboratory values were determined.
In addition, potentially relevant patient-related (body weight, smoking
status, sex), disease-related (diagnosis, disease duration as well as
Harvey-Bradshaw index, number of surgeries, disease location, behav-
iour and age at diagnosis per Montreal classification for Crohn's dis-
ease and disease severity per Montreal classification for ulcerative
colitis ) and therapy-related (dosing, premedication with corticoste-
roids, co-therapy with immunomodulators) characteristics were
recorded.
Concentrations of IFX were determined using the IDK monitor
enzyme-linked immunosorbent assay (Immunodiagnostik AG,
Bensheim, Germany12) and concentrations of ADA by a homogeneous
liquid-phase mobility shift assay (Prometheus Anser ADA, Prometheus
Laboratories Inc., San Diego, California, USA13), with a threshold for
positive ADA (ie, lower limit of quantification) of 3.13 U/mL.
2.2 | PK/PD model development by
pharmacometric analysis
Prior to PK/PD model development, statistical and graphical analyses
were performed. Thereafter the data were analysed using the
What is already known about this subject
• Clearance of infliximab (IFX) is subjected to high inter-
individual variability, prompting the need for Therapeutic
Drug Monitoring (TDM) to counteract loss-of-response in
inflammatory bowel diseases (IBD).
• C-reactive protein (CRP) is routinely measured as a bio-
marker to monitor the activity of IBD.
• Quantitative and kinetic knowledge of the relationship
between IFX exposure and disease response is scarce.
What this study adds
• A population pharmacokinetic/pharmacodynamic model
describing the inhibitory effects of IFX on CRP synthesis
was developed.
• High variability in IFX effect suggests that CRP monitor-
ing should be included in the clinical decision making.
• Based on simulations from the model, dosing adjustments
are suggested to support achieving continuous CRP
remission.
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nonlinear mixed-effects modelling approach.14 For model develop-
ment, the software tools NONMEM (version 7.3, ICON Plc, Ireland)
and PsN (version 4.7.0) were employed, while R (version 3.3) and
RStudio (version 1.1.447) were used for pre- and post-processing. The
modelling process consisted of three main parts: (a) development of
the base model characterising IFX PK, (b) covariate analysis aiming to
identify patient-, disease- or therapy-specific factors significantly
influencing IFX exposure and (c) development of a PK/PD model that
quantifies the kinetic relationship between IFX exposure and disease
activity as measured by CRP concentrations. The details of the model-
ling steps are given in the Supporting Information. Briefly, the crucial
aspects were as follows:
a. The base model comprises a structural submodel that predicts the
PK of IFX in a typical individual of the patient population and a sta-
tistical submodel which quantifies between- and within-patient
variability in the PK profiles.
b. The covariate model enables identification of patient, disease or
therapy factors that relevantly affect the PK profile, thus enabling
individualisation of the IFX concentration-time profile according to
these relevant factors.
c. In the course of PK/PD model development, the effect of IFX on
CRP was implemented via sequential PK/PD modelling, ie, after
the PK model including covariates was developed the IFX
concentration predicted for each individual (based on the so-called
empirical Bayesian estimates of the PK parameters) were used for
PD model development.15 To account for the time delay in
changes of CRP concentration induced by IFX, indirect effect
models were chosen.15 The quality and predictive performance of
the ultimate PK/PD model was assessed by a recommended
approach, the prediction-corrected visual predictive check
(n = 1000 simulations).16
2.3 | Assessment of standard dosing strategy
The developed PK/PD model was utilised to evaluate the current dos-
ing strategy in terms of CRP remission (defined as CRP < 5 mg/L17)
and this strategy was compared to potential alternative dosing strate-
gies to select the most beneficial dosing approach(es). Stochastic sim-
ulations (n = 1000) were performed for a typical IBD patient and
patients differing in the most influential covariate factors identified.
As it has previously been shown that changing the dosing interval is
superior to changes in administered dose with respect to adjustment
of IFX exposure,18 the standard dosing regimen (5 mg/kg at weeks 0,
2, 6 and every 8 weeks (q8w) afterwards) was compared to alternative
dosing regimens that differed in dosing intervals. The investigations
were focused on maintenance phase since no clinical data from the
induction phase was available in the dataset underlying the developed
model. Dosing intervals investigated ranged from every 4 (q4w) to
every 12 weeks (q12w). For recommending alternative IFX dosing reg-
imens, the time after IFX dosing when CRP concentration reached
values ≥5 mg/L (CRP nonremission) was calculated for each regimen
and compared for ADA+ and ADA− patients across the investigated
dosing intervals in the presence and absence of co-therapy with
immunomodulators.
3 | RESULTS
3.1 | PK/PD model development by
pharmacometric analysis
The details of the model development process and outcomes are
given in the Supporting Information. Altogether, 388 blood samples
scattered over the entire dosing interval after IFX dosing from
121 patients were available for PK analysis (Table 1). Table 2 and
Figure 1 give characteristics of measurements, demonstrating two
sampling periods in this study: (a) from 2 to 6 weeks (mid-term) and
(b) from 6 to 10 weeks (end of interval). The IFX concentration-time
profiles were adequately characterised by the developed two-
compartment PK model with linear elimination (Figure 2). Subse-
quently, four significant covariates (Supporting Information Figure S3)
on clearance (CL) were identified: The development of ADA in a
patient increased IFX CL by 97%, leading to an accelerated half-life
and reduced exposure of IFX, whereas co-therapy with immunomodu-
lators decreased IFX CL by 15.3%. Furthermore, low serum albumin
concentration and high body weight were related to increased CL and
thus decreased IFX exposure. Based on bootstrap (Supporting Infor-
mation Figure S2), albumin concentration of 33 g/L was in almost
100% of cases related to increase in CL of >20% compared to the ref-
erence value. The extent of the effect of body weight was more mod-
est, with both high (96 kg) and low (50 kg) values related to <20%
change in CL compared to the reference value.
The developed PK model adequately described the measured
IFX data (Supporting Information Figure S1). Volumes of distribu-
tion and intercompartmental exchange capacity values were in the
range of typical PK parameters for monoclonal antibodies (mAbs;
Supporting Information Table S1). Clearance in this study was
0.0126 L/h for the typical patient, having a body weight of 70 kg
and serum albumin concentration of 43 g/L, that did not develop
ADA and was not cotreated with immunomodulators. All covariates
were considered time-varying, implying that CL changed over time
with the covariates in each individual patient. Potential additional
time-variance of CL on top of covariate effects could not be iden-
tified. From the covariates identified as significant, ADA presence
had by far the highest impact: patients developing ADA (ADA+)
revealed an approximately 2-fold higher CL compared to ADA−
patients (Supporting Information Figure S2).
The concentration of CRP was determined in 339 blood samples.
The graphical analysis indicated that there was a strong relation
between IFX and CRP concentrations (Figure 3): CRP increased with
decreasing IFX concentration (Figure 3A). Using the IFX threshold
concentrations described in the literature (3 and 7 μg/mL), this trend
was also clearly visible on stratification into three groups: IFX under-
exposed, within the target range and overexposed (Figure 3B). This
was confirmed by statistical comparison: the relationship between
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IFX and disease activity measures was highest for CRP (Spearman's
rank correlation: 2 × 10−10, 2 × 10−5 and 0.003 for CRP, albumin
and Harvey-Bradshaw index, respectively). Correlation between CRP
and serum albumin concentrations was significant (P < 10−10),
contrary to the correlation between CRP and Harvey-Bradshaw
index (P > .1).
Leveraging mechanistic knowledge on the immunological CRP
kinetics, an inhibition of CRP synthesis by IFX exposure was assumed
and realised in the PK/PD model.4 To explore a potential difference in
CD and UC subpopulation regarding serum CRP concentrations, multi-
ple approaches were undertaken: the exploratory analysis prior to
modelling identified no difference in CRP concentration range after
first or previous dose between CD and UC, the relation between IFX
and CRP was statistically significant (P value <10−4) in both subpopu-
lations and during model development no effect of IBD type was iden-
tified on baseline CRP and/or drug efficacy (IC50). The PK/PD model
that adequately described (Supporting Information Figure S4) the rela-
tionship between IFX exposure and CRP concentration comprised an
indirect response Emax model (Figure 2) that accounted for time delay
in CRP change induced by IFX. The degradation rate constant of CRP
was fixed to correspond to a reported half-life of 19 hours
(0.0365 h−1) to avoid identification issues.20 The generated quantita-
tive and kinetic model showed that IFX has the potential to inhibit up
to 72% of CRP synthesis in a patient (Figure 4A). IFX concentration
leading to 50% of the maximum CRP synthesis inhibition was
2.04 μg/mL and IFX concentration leading to 90% of the maximum
CRP synthesis inhibition was 18.4 μg/mL. The time point when these
values were reached was naturally dependent on covariates defining
the PK profile, as demonstrated in Figure 4B. The baseline CRP con-
centration could be estimated to be 6.32 mg/L for the typical individ-
ual, with high between-patient variability (coefficient of variation; CV)
of 115% CV (5th-95th percentile range based on 1000 simulations:
1.50-28.4 mg/L). Similarly, between-patient variability in IFX concen-
tration leading to half-maximum effect was found to be very high
(209% CV; Figure 4C,D). None of the investigated covariates
(eg diagnosis, sex, smoking status, age at diagnosis, Crohn's disease
behaviour, Crohn's disease location, Montreal classification of ulcera-
tive colitis severity, number of surgeries, baseline body weight, time
since diagnosis at first IFX infusion) explained a significant part of the
variability.
3.2 | Assessment of standard dosing strategy
To evaluate the standard and alternative dosing regimens, simulations
were performed for a typical patient for nine different dosing intervals
(q4w-q12w). Figure 5A shows the distribution of time to loss of CRP
remission (CRP > 5 mg/L) for ADA+ and ADA− patients with (upper
panel) and without (lower panel) co-therapy with immunomodulators
in dependence of the dosing interval. The numbers below the boxes
show the number of patients that experienced CRP > 5 mg/L at any
point during a dosing interval: With the standard dosing regimen in
the maintenance phase (q8w), more than half of ADA+ patients expe-
rience CRP nonremission, regardless of immunomodulator use. How-
ever, co-therapy with immunomodulators significantly decreased the
proportion of patients experiencing CRP nonremission from 74% to
55%. In Figure 5B, median times to loss of CRP remission per dosing
interval were extracted. To increase the number of patients that
accomplish CRP remission over the whole dosing interval, a dosing





Sex (n = 121)
Male 62 (51.2)
Female 59 (48.8)




Diagnosis (n = 121)
Crohn's disease 88 (72.7)
Ulcerative colitis 32 (26.4)
Indeterminable IBD 1 (0.9)
Age at diagnosis of Crohn's disease
(n = 88)
≤16 years 11 (12.5)
17-40 years 65 (73.9)
>40 years 12 (13.6)




Crohn's disease behaviour (n = 87)
Nonstricturing, nonpenetrating 30 (34.5)
Stricturing 25 (28.7)
Penetrating 32 (36.8)









Continuous characteristics Median (minimum, maximum)
Body weight (kg) 70 (47, 115)
Height (cm) 171 (155, 190)
Body mass index (kg/m2) 23.2 (14.5, 41.7)
IBD, irritable bowel disease.
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interval shorter than the standard regimen would be required in both
ADA+ and ADA− patient subpopulations: To this end, in the absence
of co-therapy with immunomodulators, dosing intervals superior to
q8w would be q7w and q5w for ADA− and ADA+ patients, respec-
tively (Figure 5B). Furthermore, co-therapy with immunomodulators
obliviates the need for dosing interval reduction in ADA− patients
and shortens the needed dosing interval to q6w in ADA+ patients.
4 | DISCUSSION
To the best of the authors' knowledge, this is the first time that a pop-
ulation model that characterises the relationship of IFX PK to CRP
concentration as a time-varying variable in IBD has been reported:
This analysis characterised IFX exposure and its inhibition of CRP syn-
thesis, and thereby enabled quantification of relevant PK and PD
parameters, including variability in IFX exposure and response in the
population. Patients who develop ADA and have low albumin, high
BW and/or are not co-treated with immunomodulators were identi-
fied as subpopulations vulnerable to IFX underexposure. Furthermore,
the model-based investigations indicate that shortening of the stan-
dard maintenance phase dosing interval dependent on ADA status
should be considered to increase the number of patients maintaining
CRP remission.
Despite its long presence in IBD management, therapy with IFX
still faces challenges calling for further optimisation, from immunoge-
nicity, to variable induction drug response, to loss of response to the
therapy over time. The relationship between IFX exposure and CRP
TABLE 2 Summary of blood samples (ntotal = 388, nmid-interval = 202, nend-interval = 177) characteristics
Categorical characteristics Number of total samples (%) Number of mid-interval samples (%) Number of trough samples (%)
Concomitant therapy with immunomodulators
Yes 68 (17.5) 31 (15.3) 25 (14.0)
No 320 (82.5) 172 (84.7) 154 (86.0)
Antidrug antibodies
Yes 82 (21.1) 41 (20.3) 41 (23.2)
No 306 (78.9) 161 (79.7) 136 (76.8)
Continuous characteristics Median (minimum, maximum) Median (minimum, maximum) Median (minimum, maximum)
Absolute dose administered [mg] 400 (100, 1,300) … …
Concentration of IFX (μg/mL) (n = 388) 8.30 (0.10, 53.5) 13.8 (0.10,52.0) 4.30 (0.10, 24.0)
Concentration of CRP (mg/L) (n = 339) 2.70 (0.20, 120) 2.80 (0.20,120) 2.35 (2.00, 50.8)
Concentration of Alb (g/L) (n = 312) 42.9 (25.3, 51.6) 43.0 (25.3, 50.8) 42.7 (25.8, 51.6)
Harvey-Bradshaw index (n = 236) 2 (0, 19) 2 (0, 18) 2 (0, 19)
Note. Mid-interval samples were defined as samples taken between week 2 and week 6 after dose, end-of-interval (trough) samples were defined as
samples taken between week 6 and week 10 after dose.
Abbreviations: Alb, serum albumin; CRP, C-reactive protein; IFX, infliximab.
F IGURE 1 Overview of available measurements of infliximab (IFX) concentration in the investigated patient population. (A) Distribution of
sampling times over dosing interval. The samples were mainly taken at Cmin (trough) levels and at the middle of the dosing interval. The different
dosing intervals arose from clinical decisions. (B) Concentration of IFX over time after last dose. Note that the dataset informs only the later
phase of the concentration-time profile. The vertical orange line designates the standard dosing interval of 8 weeks (q8w). CIFX, measured IFX
concentration
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concentration has so far not been characterised in a quantitative and
mechanism-based way. Pharmacometric approaches enable a quanti-
tative, kinetic and mechanistic insight into the underlying PK and
PD/immunological pathways to be obtained. The developed models
can be used to support clinical decisions as part of TDM, advocated
by several national societies for the maintenance period of anti-TNFα
therapy.
The first part of this analysis characterised the PK of IFX in IBD
patients on maintenance phase treatment, including evaluation of fac-
tors that significantly contribute to the variability in IFX PK. In our
analysis, the covariates that significantly impacted CL in the investi-
gated population were ADA status, co-therapy with immunomodula-
tors, serum albumin concentration and body weight. Previously
published IFX PK models show a high level of agreement with respect
to identified covariates (eg, body size, disease activity markers, ADA,
co-medication) and our findings are also in good agreement with these
reports.21–29 In contrast to most of the previously developed models,
all covariates in the present analysis were implemented as time-
varying variables, thus implying a realistic change of IFX CL over time
relative to the covariate values in individual patients. By incorporating
the change over time in covariate values (in contrast to baseline
covariate values only), more information from a covariate-parameter
relationship from the data is used.
Mechanistically, the development of ADA affects both the PK
and IFX effects. ADA molecules binding to active sites of the IFX
molecule hinder its efficacy by disabling binding to its target, TNFα.
Furthermore, the IFX-ADA complexes formed are promptly cleared
from blood, contributing to higher CL of IFX.30 Despite differences in
assays available for ADA detection/quantification, especially the
lower limit of quantification, resulting in varying definitions of ADA
positivity in different analyses, ADA have consistently been found to
impact IFX CL. The assay used in this study quantified total
(both drug-bound and unbound) ADA concentration, with a cut-off
for ADA positivity of 3.13 U/mL. In this analysis, an approximately
2-fold higher IFX CL was found in patients who developed ADA
compared to patients who did not. The ADA status was, however, not
found to impact the drug efficacy in our model. Another important
factor that influences IFX CL is serum albumin concentration, as con-
firmed by our analysis as well. Serum albumin is likely related to IFX
CL via two mechanisms: (a) as a marker of disease state and increased
protein turnover in inflammation and (b) as a marker of the neonatal
Fc-receptor (FcRn) activity (lower albumin concentration indicative of
lower FcRn activity, resulting in higher IFX CL), potentially explaining
why albumin was the disease activity marker predictive of IFX CL
F IGURE 2 Graphical representation of the final pharmacokinetic/
pharmacodynamics (PK/PD) model. Infliximab (IFX) PK is described by
a two-compartment model with linear elimination. Antidrug antibody
status, serum albumin concentration, co-therapy with
immunomodulators and body weight were identified to impact the
drug clearance (CL). The effect of IFX on C-reactive protein (CRP) was
best characterised via the indirect drug effect modelling approach,
whereby the plasma concentration of IFX was related to inhibition of
CRP synthesis. ADA, antidrug antibodies; ALB, serum albumin
concentration; BW, body weight; CL, clearance; CRP, C-reactive
protein; IFX, infliximab; IMM, co-therapy with immunomodulators;
kdeg, rate constant of CRP degradation; ksyn, rate constant of CRP
synthesis; Q, intercompartmental exchange capacity; V1, volume of
central compartment; V2, volume of peripheral compartment
F IGURE 3 Relation between infliximab (IFX) exposure (ie, plasma concentration) and C-reactive protein (CRP) concentration.
(A) Concentration of CRP over IFX concentration. The blue line represents linear regression. (B) Simplified comparison of the IFX-CRP
relationship. Concentrations of IFX were stratified in three groups: ≤3 μg/mL, between 3 and 7 μg/mL, and >7 μg/mL.19 The numbers indicate the
number of observations each group comprises. A decrease in CRP concentration from the group with lowest IFX exposure to the group with
highest is observed. CCRP, measured CRP concentration; CIFX, measured IFX concentration
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rather than CRP. Furthermore, our analysis revealed a direct relation-
ship between body weight and IFX CL, as well as an inverse relation-
ship between co-therapy with immunomodulators and CL (see below).
This analysis also investigated the potential impact of other covariates
(eg, disease, sex), but none of them had a significant effect on
CL. Given the similar proportion of male and female patients, our
results suggest that dosing recommendations for both sexes must not
be different.
Of the myriad measures used to assess activity of IBD, bio-
markers currently represent adjunctive treatment targets primarily
aimed for disease monitoring.31 This study focused on CRP due to its
favourable characteristics: (a) correlation with endoscopy,3 (b) high
sensitivity and short half-life (t½ = approximately 19 h), and (c) well-
known kinetic behaviour that does not differ between healthy and
diseased individuals.4
One of the aims of this work was to investigate the PK/PD rela-
tionship between IFX exposure and IBD activity measures. In this
analysis, disease activity measures were CRP and serum albumin con-
centrations, and the Harvey-Bradshaw index for patients with
Crohn's disease. For UC, disease severity was assessed according to
the Montreal classification and disease activity by the partial Mayo
score; however, due to the low number of patients with UC, sub-
analyses in this group were not performed. As TNFα is the main initi-
ator of immunological cascade resulting in CRP synthesis, lower
levels of TNFα lead to lower CRP synthesis (Figure 2). Since IFX does
not inhibit CRP synthesis directly, a certain time-delay between max-
imum IFX exposure and maximum inhibition of CRP synthesis is
expected. In the PK/PD model, this time-delay was incorporated as
IFX inhibition of CRP synthesis via the indirect response modelling
approach. The model estimated that up to approximately 72% of
F IGURE 4 Illustration of infliximab (IFX) concentration (CIFX)-effect (C-reactive protein [CRP] synthesis inhibition)-time relationships. (A) IFX
exposure-CRP synthesis inhibition curve and IFX potency. Red and blue arrows designate the IFX concentrations corresponding to 90%
(18.4 μg/mL) and 50% (2.04 μg/mL) of the maximum CRP synthesis inhibition effect of 72% (dashed green line), respectively. (B) Time after
dose when IFX concentration falls below the 90% (blue line) and 50% (red line) effect concentrations for ADA− (solid lines) and ADA+ (dotted
lines) patients without (black lines) and with (green lines) immunomodulator co-therapy. (C) and (D) Visualisation of high unexplained between-
patient variability in IFX concentrations leading to a half-maximum effect on CRP concentration (IC50 value). Stochastic simulations were
performed whereby variability in IC50 was considered. (C) IFX concentration-time profile in a reference individual. (D) Corresponding potential
CRP concentration profiles. The plot demonstrates that due to high between-patient variability that could not be explained with any covariates,
even for a patient with a known PK profile and baseline CRP concentration it is not possible to predict a single corresponding CRP profile, but
rather a (rather wide) range of potential CRP profiles. ADA, antidrug antibodies; CCRP, measured CRP concentration; CIFX, measured IFX
concentration; IMM, co-therapy with immunomodulators
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F IGURE 5 Evaluation of the standard and alternative infliximab (IFX) dosing regimens with respect to C-reactive protein (CRP) suppression
via stochastic simulations (n = 1000) of patients that differ only in antidrug antibody status. For the simulations, variability in the PK submodel
parameters was considered. (a) Distribution of time points in the weeks after the fifth dose when CRP concentration reached 5 mg/L (CRP
nonremission) as box-whisker plot over simulated IFX dosing intervals, stratified by antidrug antibody (ADA) status and co-therapy with
immunomodulators. Note that the virtual patients that do not experience CRP concentrations above 5 mg/L (ie, without loss of CRP remission)
are not included in the plot. Proportions of patients experiencing CRP nonremission (shown below each box) are higher in cases of ADA
development and absence of co-therapy with immunomodulators. (b) Simplification showing only the median time after the fifth dose when CRP
concentration reached CRP nonremission stratified by ADA development and immunomodulatory co-therapy. In the presence of co-therapy with
immunomodulators, the standard IFX dosing interval of every 8 weeks (q8w) corresponds to median time to CRP nonremission in ADA− patients,
whereas for ADA+ patients reduction to q6w is to be recommended. In the absence of co-therapy with immunomodulators, for ADA− patients a
dosing interval of q7w corresponds to the median time to CRP nonremission, whereas for ADA+ patients further reduction to a dosing interval of
q5w should be preferred. Red frame, standard IFX dosing regimen every 8 weeks
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CRP synthesis can be inhibited by IFX (Figure 4A). In other words,
the IFX effect is saturable and CRP synthesis cannot be 100%
inhibited by IFX: Regardless of how high IFX concentrations are
achieved within an individual, approximately a quarter of CRP syn-
thesis cannot be inhibited. This finding, now quantified, is in good
accordance with previous knowledge, since TNFα is not the only
immunological initiator of CRP synthesis.4 Concentration of IFX lead-
ing to half-maximum effect was 2.04 μg/mL, which approximately
corresponds to PK targets previously described in the literature.19
The corresponding IFX concentration leading to 90% of the maxi-
mum effect was 18.4 μg/mL. As, depending on their covariates, dif-
ferent patients might have different PK profiles, the time after a
dose when IFX concentration falls below an effective level might dif-
fer as well. This is illustrated in Figure 4B: a typical ADA− patient
drops below the 90% effect IFX concentration before week 4 in the
absence of co-therapy with immunomodulators and after week 4 in
the presence of the co-therapy. The IFX concentration never falls
below the 50% effect concentration in this subpopulation. In con-
trast, ADA+ patients fall below the 90% effect concentration thresh-
old around week 2, regardless of immunomodulators use, ie,
approximately or more than 2x faster than the ADA− patient. Thus,
in ADA+ patients the 90% effect concentration is achieved during
only one quarter of the dosing interval. The beneficial co-therapy
with immunomodulators, however, delays crossing the 50% effect
concentration threshold in ADA+ patients from 5 to 6 weeks. From
the clinical perspective, a very important finding of this analysis is
the high between-patient variability in IC50 value of IFX for the
effect on CRP (209% CV). One hypothesis to explain the identified
high between-patient variability in IC50 is the fact that CRP is a far
downstream biomarker with respect to IFX binding to TNFα. A simi-
lar finding was recently obtained for faecal calprotectin in a report of
an IFX-faecal calprotectin PK/PD model.32 This indicates that there
is a potentially high individual difference in effect (ie, inhibition of
CRP synthesis) among patients even in cases of the same IFX expo-
sure (Figure 4C,D). Practically, this implies that monitoring of disease
activity measures, such as CRP concentration, might be advanta-
geous over solely monitoring IFX concentration. Further investiga-
tions in the direction of identifying covariates that contribute to this
high variability are warranted.
In our data, no long-term inhibitory effect of IFX on CRP was
observed, ie, stopping IFX therapy leads to increase in disease activity,
regardless of the time after IFX therapy initiation. Contrarily, clinical
experience suggests that some patients will remain in a state of
remission even if IFX therapy is ceased after a certain period.33,34 In
our data, samples were collected from a large number of patients, but
spread over different ranges of time after first dose and with a
relatively short follow-up time. This might contribute to the lack of
identification of long-term disease suppression. If long-term data is
available and this cumulative IFX effect was identified, it could be
added to the PK/PD model.
We acknowledge that our study has certain limitations. As sam-
pling in the first weeks of the dosing interval is scarce, the dataset
informs only the later phase of the IFX concentration-time profile.
This limitation manifests itself through the fact that the central vol-
ume of distribution and intercompartmental exchange capacity could
not be estimated from the data alone, in contrast to clearance and
peripheral volume of distribution. The frequentist prior approach
enabled this limitation of the real-world clinical data situation to be
overcome.35 While the sampling scheme (ie, two samples per dosing
interval) resulted in appreciable ranges of all variables (eg, IFX, CRP,
ALB, covariates) due to the TDM nature of the dataset, the CRP
concentration at the time of the first IFX infusion was not available
for most patients. Our generated model, however, was able to esti-
mate the plausible baseline CRP value very precisely. In addition,
measurement of further factors, eg, genotyping and assessment of
faecal loss of IFX, CRP and albumin, would enable investigation of
their potential effect on the PK and PK/PD. For instance, besides
the two known mechanisms of the albumin-IFX relationship (ie, the
inverse relationship between serum albumin concentration and IBD
activity, and the shared PK pathways of albumin and IFX, especially
the FcRn salvage pathway), faecal loss might be an additional con-
tributor. Finally, limitations of CRP as a disease marker (eg, lack of
specificity) have to be acknowledged; investigation of additional dis-
ease markers would add to this knowledge and help further inform
the choice of the most appropriate marker. This was accounted for
in the developed PK/PD model by a finding of maximum CRP syn-
thesis inhibition lower than 100%, whereby non-TNFα inducers of
CRP synthesis are implied. Altogether, the heterogeneity of the
patient population (covering broad ranges of the measured values)
and the informative sampling time points (including an additional
sample to the one taken just before the next IFX dose, i.e. trough)
enabled the described IFX exposure-response relationship to be
captured.
Pharmacometric nonlinear mixed-effects modelling analysis of
PK/PD relationships enables characterisation of the analysed patient
population over time in a continuous manner, at the same time pro-
viding insight into the variability between patients and relevant
covariates. One of the advantages of this modelling approach is that
after successful model development and evaluation, the model can be
employed to test different hypotheses via simulations. This is illus-
trated by the in silico substudy we carried out. As the presence of
ADA was found to lead to a very high influence on IFX CL and thus
IFX exposure, we investigated how this impact reflects on CRP. To
this end, simulations were performed for ADA+ and ADA− virtual IBD
patients to assess different dosing intervals (q4w-q12w) and the
impact of co-therapy with immunomodulators. The desired target was
defined as CRP concentration <5 mg/L over the whole dosing interval
(CRP remission). To assess the target attainment, simulations
(n = 1000) were performed for each investigated dosing interval and
(a) the percentage of patients with undesired outcome, ie, that reach
CRP > 5 mg/L (CRP nonremission) and (b) the time after the fifth dose
when the CRP concentration crossed and exceeded the target value
were recorded. As shown in Figure 5A, when a standard dosing
regimen (q8w) was simulated without co-therapy with
immunomodulators, 10% of ADA− and as much as 74% of ADA+
patientsexperienced CRP values higher than 5 mg/L. These
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proportions were lower in the presence of immunomodulators (5%
and 55% for ADA− and ADA+ patients, respectively). The median
time to loss of CRP remission (Figure 5B) suggests that ADA− patients
accomplish continuous CRP remission with standard dosing interval
q8w when they are co-treated with immunomodulators. On the other
hand, in ADA+ patients a reduction of dosing interval would be
required to q5w and q6w in the absence and presence of immuno-
modulators co-therapy, respectively.
In this study, we report the first PK/PD model relating IFX expo-
sure to inhibition of CRP synthesis in IBD patients. Increased CL of
IFX was related to development of ADA, low serum albumin, high
body weight and absence of co-therapy with immunomodulators. The
developed PK/PD model identified high variability in effect on CRP
for the same IFX exposure, which could not be explained with
evaluated covariates, suggesting individual CRP measurements should
be monitored and included in the decision of a patient's dosing
regimen. Based on simulations from the developed PK/PD model,
concrete ADA status- and immunomodulatory co-therapy-dependent
dosing adjustments of current standard dosing strategies are
suggested to support achieving continuous CRP remission in these
patients. Finally, the developed model enables simulation of any type
of dosing regimen change (eg, dose change) and provides a framework
for development of a dashboard system28 that could directly support
therapeutic decision making, with respect to achieving both IFX and
CRP targets.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY, and are permanently archived in the Concise
Guide to PHARMACOLOGY 2019/20.36
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